|
1）Dang NC, Topkara VK, Mercando M, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant. 2006; 25: 1-6
|
|
|
|
2）Patel ND, Weiss ES, Schaffer J, et al. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. Ann Thorac Surg. 2008; 86: 832-40
|
|
|
|
|
|
3）Larose E, Ganz P, Reynolds HG, et al. Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction. J Am Coll Cardiol. 2007; 49: 855-62
|
|
|
|
|
|
4）Meyer P, Filippatos GS, Ahmed MI, et al. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation. 2010; 121: 252-8
|
|
|
|
|
|
5）Shiina Y, Toyoda T, Kawasoe Y, et al. Prevalence of adult patients with congenital heart disease in Japan. Int J Cardiol. 2011; 146: 13-6
|
|
|
|
|
|
6）Haddad F, Hunt SA, Rosenthal DN, et al. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation. 2008; 117: 1436-48
|
|
|
|
|
|
7）Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010; 121: 20-5
|
|
|
|
|
|
8）Vonk-Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension： physiology and pathobiology. J Am Coll Cardiol. 2013; 62: D22-33
|
|
|
|
|
|
9）Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res. 2014; 115: 176-88
|
|
|
|
|
|
10）Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis. 2005; 16: 13-8
|
|
|
|
|
|
11）Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30: 2493-537
|
|
|
|
|
|
12）van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011; 58: 2511-9
|
|
|
|
|
|
13）Mauritz GJ, Kind T, Marcus JT, et al. Progressive changes in right ventricular geometric shortening and long-term survival in pulmonary arterial hypertension. Chest. 2012; 141: 935-43
|
|
|
|
|
|
14）te Riele AS, Bhonsale A, James CA, et al. Incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardio-myopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013; 62: 1761-9
|
|
|
|
|
|
15）Doesch C, Dierks DM, Haghi D, et al. Right ventricular dysfunction, late gadolinium enhancement, and female gender predict poor outcome in patients with dilated cardiomyopathy. Int J Cardiol. 2014; 177: 429-35
|
|
|
|
|
|
16）Junqueira FP, Macedo R, Coutinho AC, et al. Myocardial delayed enhancement in patients with pulmonary hypertension and right ventricular failure: evaluation by cardiac MRI. Br J Radiol. 2009; 82: 821-6
|
|
|
|
|
|
17）Freed BH, Gomberg-Maitland M, Chandra S, et al. Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson. 2012; 14: 11
|
|
|
|
|
|
18）Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography, a registerd branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010; 23: 685-713
|
|
|
|
|
|
19）Kassem E, Humpl T, Friedberg MK. Prognostic significance of 2-dimensional, M-mode, and Doppler echo indices of right ventricular function in children with pulmonary arterial hypertension. Am Heart J. 2013; 165: 1024-31
|
|
|
|
|
|
20）Mercer-Rosa L, Parnell A, Forfia PR, et al. Tricuspid annular plane systolic excursion in the assessment of right ventricular function in children and adolescents after repair of tetralogy of Fallot. J Am Soc Echocardiogr. 2013; 26: 1322-9
|
|
|
|
|
|
21）Sugeng L, Mor-Avi V, Weinert L, et al. Multimodality comparison of quantitative volumetric analysis of the right ventricle. JACC Cardiovasc Imaging. 2010; 3: 10-8
|
|
|
|
|
|
22）La Gerche A, Burns AT, Mooney DJ, et al. Exercise-induced right ventricular dysfunction and structural remodelling in endurance athletes. Eur Heart J. 2012; 33: 998-1006
|
|
|
|
|
|
23）Haddad F, Hunt SA, Rosenthal DN, et al. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation. 2008; 117: 1436-48
|
|
|
|
|
|
24）Hardegree EL, Sachdev A, Villarraga HR, et al. Role of serial quantitative assessment of right ventricular function by strain in pulmonary arterial hypertension. Am J Cardiol. 2013; 111: 143-8
|
|
|
|
|
|
25）Focardi M, Cameli M, Carbone SF, et al. Traditional and innovative echocardiographic parameters for the analysis of right ventricular performance in comparison with cardiac magnetic resonance. Eur Heart J Cardiovasc Imaging. 2014. Sep 3. pii: jeu 156. [Epub ahead of print]
|
|
|
|
|
|
26）Smith BC, Dobson G, Dawson D, et al. Three-dimensional speckle tracking of the right ventricle: toward optimal quantification of rightventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol. 2014; 64: 41-51
|
|
|
|
|
|
27）Lau EM, Manes A, Celermajer DS, et al. Early detection of pulmonary vascular disease in pulmonary arterial hypertension: time to move forward. Eur Heart J. 2011; 32: 2489-98
|
|
|
|
|
|
28）Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009; 179: 151-7
|
|
|
|
|
|
29）Ait-Ali L, Siciliano V, Passino C, et al. Role of stress echocardiography in operated Fallot: feasibility and detection of right ventricular response. J Am Soc Echocardiogr. 2014; 27: 1319-28
|
|
|
|
|
|
30）Kusunose K, Popović ZB, Motoki H, et al. Prognostic significance of exercise-induced right ventricular dysfunction in asymptomatic degenerative mitral regurgitation. Circ Cardiovasc Imaging. 2013; 6: 167-76
|
|
|
|
|
|
31）Montani D, Chaumais MC, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther. 2014; 141: 172-91
|
|
|
|
|
|
32）Zochios V, Jones N. Acute right hear syndrome in the critically ill patients. Heart Lung Vessles. 2014; 6: 157-70
|
|
|
|
|
|
33）Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation. 1992; 86: 12-21
|
|
|
|
|
|
34）de Man FS, Handoko ML, van Ballegoij JJ, et al. Bisoprolol delays progression towards right heart failure in experimental pulmonary hypertension. Circ Heart Fail. 2012; 5: 97-105
|
|
|
|
|
|
35）Thenappan T, Roy SS, Duval S, et al. β-Blocker Therapy Is Not Associated With Adverse Outcomes in Patients With Pulmonary Arterial Hypertension: A Propensity Score Analysis. Circ Heart Fail. 2014; 7: 903-10
|
|
|
|
|
|
36）Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007; 116: 238-48
|
|
|
|
|
|
37）Gomez-Arroyo J, Sakagami M, Syed AA, et al. Iloprost reverses established fibrosis in experimental right ventricular failure. Eur Respir J. 2014 Sep 26. pii: erj 01880-2013. [Epub ahead of print]
|
|
|
|
|
|
38）Piao L, Fang Y-H, Cadete VJJ, et al. The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med. 2010; 88: 47-60
|
|
|
|
|
|
39）Hardziyenka M, Surie S, de Groot JR, et al. Right ventricular pacing improves haemodynamics in right ventricular failure from pressure overload: an open observational proof-of-principle study in patients with chronic thromboembolic pulmonary hypertension. Europace. 2011; 13: 1753-9
|
|
|
|
|